Akero Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Akero Therapeutics filed a supplement to its definitive proxy statement for the upcoming special meeting, providing additional disclosures regarding its proposed merger with Novo Nordisk and addressing two stockholder lawsuits.
Akero Therapeutics stockholders are invited to a special meeting on December 2, 2025, to vote on the proposed acquisition by Novo Nordisk A/S for $54.00 cash per share plus a $6.00 contingent value right.
Novo Nordisk has entered into an agreement to acquire Akero Therapeutics for $54.00 per share in cash plus a Contingent Value Right of $6.00, totaling an equity value of approximately $5.2 billion if milestones are met.
Akero Therapeutics has agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash, including a contingent value right tied to regulatory approval of efruxifermin.
Akero Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 3, 2025, featuring proposals for director elections, auditor ratification, and executive compensation approval.
Akero Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 7, 2024, to vote on key proposals, including the election of directors, ratification of the accounting firm, executive compensation, and an amendment to limit officer liability.